{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.79","value":"0.1"},{"groupId":"OG001","spread":"9.12","value":"-2.2"},{"groupId":"OG002","spread":"8.89","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"142"}],"units":"Participants"}],"title":"DBP Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.61","value":"-1.1"},{"groupId":"OG001","spread":"8.01","value":"-2.8"},{"groupId":"OG002","spread":"9.34","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"168"},{"groupId":"OG002","value":"156"}],"units":"Participants"}],"title":"DBP Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.05","value":"0.1"},{"groupId":"OG001","spread":"9.19","value":"-2.8"},{"groupId":"OG002","spread":"8.83","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"124"}],"units":"Participants"}],"title":"DBP Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.81","value":"0"},{"groupId":"OG001","spread":"8.95","value":"-2.7"},{"groupId":"OG002","spread":"8.96","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"title":"DBP Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.25","value":"-0.6"},{"groupId":"OG001","spread":"8.56","value":"-2.3"},{"groupId":"OG002","spread":"8.67","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"84"}],"units":"Participants"}],"title":"DBP Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.87","value":"1.1"},{"groupId":"OG001","spread":"11.08","value":"-0.3"},{"groupId":"OG002","spread":"10.40","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"136"}],"units":"Participants"}],"title":"DBP End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.35","value":"-0.9"},{"groupId":"OG001","spread":"13.12","value":"-2.3"},{"groupId":"OG002","spread":"13.94","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"142"}],"units":"Participants"}],"title":"SBP Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.44","value":"-2.2"},{"groupId":"OG001","spread":"13.70","value":"-3.4"},{"groupId":"OG002","spread":"13.39","value":"-2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"168"},{"groupId":"OG002","value":"156"}],"units":"Participants"}],"title":"SBP Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.11","value":"-0.6"},{"groupId":"OG001","spread":"14.78","value":"-3.7"},{"groupId":"OG002","spread":"14.98","value":"-1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"124"}],"units":"Participants"}],"title":"SBP Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.59","value":"-0.2"},{"groupId":"OG001","spread":"14.36","value":"-2.7"},{"groupId":"OG002","spread":"14.14","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"title":"SBP Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.78","value":"-0.2"},{"groupId":"OG001","spread":"15.30","value":"-2.1"},{"groupId":"OG002","spread":"13.96","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"84"}],"units":"Participants"}],"title":"SBP Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.21","value":"-0.9"},{"groupId":"OG001","spread":"16.83","value":"-1.0"},{"groupId":"OG002","spread":"15.92","value":"-3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"136"}],"units":"Participants"}],"title":"SBP End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"description":"Vital signs included blood pressure and pulse rate. Changes from baseline in sitting diastolic blood pressure (DBP) and systolic blood pressure (SBP) were summarized.","dispersionType":"Standard Deviation","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEAN","populationDescription":"'Number of Participants Analyzed' is based on the safety analysis set, which included all participants who received at least 1 dose of study treatment. 'Number Analyzed' included the number of participants in the safety analysis set with at least a baseline and post-baseline assessment at the visit.","reportingStatus":"POSTED","timeFrame":"From screening to the end of treatment/withdrawal visit, up to 2.7 years, based on cutoff date: 19 September 2018.","title":"Change From Baseline in Vital Signs - Blood Pressure","type":"SECONDARY","unitOfMeasure":"mm Hg"}